Interpace Biosciences Inc
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis of pancreaticobiliary cancers using its proprietary PathFinderTG platform; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an … Read more
Interpace Biosciences Inc (IDXG) - Total Liabilities
Latest total liabilities as of September 2025: $12.33 Million USD
Based on the latest financial reports, Interpace Biosciences Inc (IDXG) has total liabilities worth $12.33 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Interpace Biosciences Inc - Total Liabilities Trend (2000–2024)
This chart illustrates how Interpace Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Interpace Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Interpace Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CopperEx Resources Corporation
V:CUEX
|
Canada | CA$286.39K |
|
Digistar Corporation Bhd
KLSE:0029
|
Malaysia | RM223.59 Million |
|
Pila Pharma AB
ST:PILA
|
Sweden | Skr1.43 Million |
|
DONTNOD Entertainment SA
PA:ALDNE
|
France | €12.65 Million |
|
Tactical Resources Corp.
PINK:USREF
|
USA | $8.61 Million |
|
MBB (MBB.SG)
STU:MBB
|
Germany | €360.23 Million |
|
Merino & Co. Ltd
AU:MNC
|
Australia | AU$4.71 Million |
|
Mint Corp
V:MIT
|
Canada | CA$888.36K |
Liability Composition Analysis (2000–2024)
This chart breaks down Interpace Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -41.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Interpace Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Interpace Biosciences Inc (2000–2024)
The table below shows the annual total liabilities of Interpace Biosciences Inc from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $17.01 Million | -77.23% |
| 2023-12-31 | $74.69 Million | -5.51% |
| 2022-12-31 | $79.05 Million | +130.41% |
| 2021-12-31 | $34.31 Million | +21.54% |
| 2020-12-31 | $28.23 Million | -5.42% |
| 2019-12-31 | $29.85 Million | +92.51% |
| 2018-12-31 | $15.50 Million | +12.93% |
| 2017-12-31 | $13.73 Million | -61.05% |
| 2016-12-31 | $35.25 Million | -35.53% |
| 2015-12-31 | $54.67 Million | -42.92% |
| 2014-12-31 | $95.78 Million | +161.81% |
| 2013-12-31 | $36.59 Million | -14.55% |
| 2012-12-31 | $42.82 Million | -20.50% |
| 2011-12-31 | $53.86 Million | -1.86% |
| 2010-12-31 | $54.88 Million | +57.30% |
| 2009-12-31 | $34.89 Million | -16.80% |
| 2008-12-31 | $41.93 Million | +6.51% |
| 2007-12-31 | $39.37 Million | -24.93% |
| 2006-12-31 | $52.44 Million | -18.95% |
| 2005-12-31 | $64.70 Million | +9.14% |
| 2004-12-31 | $59.28 Million | -26.94% |
| 2003-12-31 | $81.14 Million | +19.80% |
| 2002-12-31 | $67.73 Million | -55.36% |
| 2001-12-31 | $151.74 Million | +14.85% |
| 2000-12-31 | $132.12 Million | -- |